Clinical Trial Update: CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors [NA]

View source ↗

Summary

A clinical trial is evaluating a CLDN18.2-targeting nanobody PET imaging probe for solid tumors; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• CLDN18.2-targeting nanobody PET probe

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Solid Tumor | NA | Status: RECRUITING